Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.78 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.62 |
| ▸ | IGF2R | P11717 | 4/20 | 0.58 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.44 |
| ▸ | UMPS | P11172 | 2/20 | 0.43 |
| ▸ | ATIC | P31939 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4323207 | 1.00 | FBP1 (0.78) | FBP1AMDHD2IGF2RP2RY14UMPS | |
| SCHEMBL15628068 | 1.00 | FBP1 (0.78) | FBP1AMDHD2IGF2RP2RY14UMPS | |
| SCHEMBL977102 | 1.00 | FBP1 (0.78) | FBP1AMDHD2IGF2RP2RY14UMPS | |
| SCHEMBL9117406 | 1.00 | FBP1 (0.78) | FBP1AMDHD2IGF2RP2RY14UMPS | |
| SCHEMBL345396 | 1.00 | FBP1 (0.78) | FBP1AMDHD2IGF2RP2RY14UMPS | |
| SCHEMBL12377166 | 1.00 | FBP1 (0.78) | FBP1AMDHD2IGF2RP2RY14UMPS | |
| SCHEMBL799813 | 1.00 | FBP1 (0.78) | FBP1AMDHD2IGF2RP2RY14UMPS | |
| SCHEMBL48379 | 1.00 | FBP1 (0.78) | FBP1AMDHD2IGF2RP2RY14UMPS | |
| SCHEMBL21926734 | 1.00 | FBP1 (0.78) | FBP1AMDHD2IGF2RP2RY14UMPS | |
| SCHEMBL22107998 | 1.00 | FBP1 (0.78) | FBP1AMDHD2IGF2RP2RY14UMPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 934 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3620510-B2 | FERMENTATIVE PRODUCTION OF OLIGOSACCHARIDES BY TOTAL FERMENTATION UTILIZING A MIXED FEEDSTOCK | CHR HANSEN HMO GMBH (DE) | 2026-05-27 | — | — | EP | claimed |
| US-12636363-B2 | Anti-transferrin receptor fusion proteins and methods of use thereof | DENALI THERAPEUTICS INC. (US) | 2026-05-26 | — | — | US | claimed |
| CN-122060031-A | Alpha 2 delta 1 targeted degradation molecule alpha 2 delta 1-LYTAC, derivative thereof and application | 暨南大学 | 2026-05-19 | — | — | CN | claimed |
| US-12622952-B2 | Formulations comprising recombinant acid α-glucosidase | AMICUS THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | claimed |
| WO-2026090085-A1 | TREATMENT OF CD33 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-3187508-B1 | LYSOSOMAL TARGETING PEPTIDES AND USES THEREOF | BIOMARIN PHARM INC (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260077025-A1 | SIALYLATED GLYCOPROTEIN COMPOSITION AND USES THEREOF | ULTRAGENYX PHARMACEUTICAL INC (US) | 2026-03-19 | — | — | US | claimed |
| EP-3924473-B1 | ENZYMATIC PRODUCTION OF MANNOSE | BONUMOSE INC (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250387477-A1 | ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | claimed |
| US-20250367284-A1 | ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS INC. (US) | 2025-12-04 | — | — | US | claimed |
| US-11357834-B2 | Recombinant α-galactosidase A for treatment of Fabry disease | AMICUS THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | claimed |
| US-20220162578-A1 | HIGHLY POTENT ACID ALPHA-GLUCOSIDASE WITH ENHANCED CARBOHYDRATES | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-05-26 | — | — | US | claimed |
| EP-3997214-A1 | CHEMICALLY-MODIFIED ADENO-ASSOCIATED VIRUS | Centre national de la recherche scientifique (FR) | 2022-05-18 | — | — | EP | claimed |
| US-20220127591-A1 | LYSOSOMAL ENZYMES MODIFIED BY CELL BASED GLYCOENGINEERING | GLYCODISPLAY APS (DK) | 2022-04-28 | — | — | US | claimed |
| US-20220127653-A1 | ENZYMATIC PRODUCTION OF MANNOSE | X-CALIBER RURAL CAPITAL, LLC | 2022-04-28 | — | — | US | claimed |
| CN-109475607-B | Formulations comprising recombinant acid alpha-glucosidase | 阿米库斯治疗学公司 | 2022-04-26 | — | — | CN | claimed |
| US-20220119547-A1 | SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES | GENZYME CORPORATION | 2022-04-21 | — | — | US | claimed |
| EP-3436053-B1 | FORMULATIONS COMPRISING RECOMBINANT ACID ALPHA-GLUCOSIDASE | AMICUS THERAPEUTICS INC (US) | 2022-04-06 | — | — | EP | claimed |
| EP-3946243-A1 | ANTI-AGING COSMETIC COMPOSITION | Givaudan SA (CH) | 2022-02-09 | — | — | EP | claimed |
| EP-1883394-B1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2018-03-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636363-B2 | Anti-transferrin receptor fusion proteins and methods of use thereof | IDUA, TFRC, TPST2 | FBP1 432/4885AMDHD2 1224/4885IGF2R 34/4885 |
| US-12622952-B2 | Formulations comprising recombinant acid α-glucosidase | MAN2B1, MAN2A1, MANBA | FBP1 134/4885AMDHD2 218/4885IGF2R 53/4885 |
| US-20220119547-A1 | SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES | CD2BP2, CD74, ENGASE | FBP1 1501/4885AMDHD2 914/4885IGF2R 115/4885 |
| US-20250387477-A1 | ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF | TFRC, IDUA, TPST2 | FBP1 560/4885AMDHD2 1150/4885IGF2R 35/4885 |
| US-20260077025-A1 | SIALYLATED GLYCOPROTEIN COMPOSITION AND USES THEREOF | M6PR, NEU2, NEU4 | FBP1 566/4885AMDHD2 368/4885IGF2R 26/4885 |
| US-11357834-B2 | Recombinant α-galactosidase A for treatment of Fabry disease | GLA, GAA, GBA1 | FBP1 416/4885AMDHD2 109/4885IGF2R 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.